ES2843546T3 - Anticuerpos humanizados anti-antígeno-TF - Google Patents

Anticuerpos humanizados anti-antígeno-TF Download PDF

Info

Publication number
ES2843546T3
ES2843546T3 ES15780559T ES15780559T ES2843546T3 ES 2843546 T3 ES2843546 T3 ES 2843546T3 ES 15780559 T ES15780559 T ES 15780559T ES 15780559 T ES15780559 T ES 15780559T ES 2843546 T3 ES2843546 T3 ES 2843546T3
Authority
ES
Spain
Prior art keywords
antibody
jaa
mouse
humanized
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES15780559T
Other languages
English (en)
Spanish (es)
Inventor
Kate Rittenhouse-Olson
Julia Abdullah
Jing Ying Eng
Stephen T Koury
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Research Foundation of the State University of New York
Original Assignee
Research Foundation of the State University of New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Research Foundation of the State University of New York filed Critical Research Foundation of the State University of New York
Application granted granted Critical
Publication of ES2843546T3 publication Critical patent/ES2843546T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
ES15780559T 2014-04-18 2015-04-20 Anticuerpos humanizados anti-antígeno-TF Active ES2843546T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461981240P 2014-04-18 2014-04-18
PCT/US2015/026595 WO2015161311A2 (en) 2014-04-18 2015-04-20 Humanized anti-tf-antigen antibodies

Publications (1)

Publication Number Publication Date
ES2843546T3 true ES2843546T3 (es) 2021-07-19

Family

ID=54324717

Family Applications (1)

Application Number Title Priority Date Filing Date
ES15780559T Active ES2843546T3 (es) 2014-04-18 2015-04-20 Anticuerpos humanizados anti-antígeno-TF

Country Status (11)

Country Link
US (1) US11130821B2 (enExample)
EP (2) EP3797793A1 (enExample)
JP (1) JP6740135B2 (enExample)
KR (1) KR102413809B1 (enExample)
CN (1) CN106488774B (enExample)
AU (1) AU2015247358B2 (enExample)
BR (1) BR112016024214B8 (enExample)
ES (1) ES2843546T3 (enExample)
MX (2) MX378944B (enExample)
RU (1) RU2699717C2 (enExample)
WO (1) WO2015161311A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2019012233A (es) * 2017-04-13 2020-01-14 Aduro Biotech Holdings Europe Bv Anticuerpos anti-sirpa.
EP3684409A4 (en) * 2017-09-22 2021-06-23 Immunogen, Inc. SEPARATION OF TRIPLE LIGHT CHAIN ANTIBODIES USING CATION EXCHANGE CHROMATOGRAPHY
MX2020010110A (es) * 2018-03-28 2020-11-06 Mitsubishi Tanabe Pharma Corp Conjugados de farmacos de agentes de union monoclonales de cmet, y usos de los mismos.
WO2019231957A1 (en) * 2018-05-30 2019-12-05 National Health Research Institutes Anti-abeta antibodies and uses thereof
KR20210107062A (ko) 2018-12-21 2021-08-31 오제 이뮈노테라프틱스 이작용성 항-PD-1/SIRPα 분자
EP3898677A1 (en) 2018-12-21 2021-10-27 OSE Immunotherapeutics Bifunctional anti-pd-1/il-7 molecule
CN113573782B (zh) 2018-12-21 2025-12-16 Ose免疫疗法公司 针对人pd-1的双功能分子
MX390775B (es) 2018-12-21 2025-03-21 Ose Immunotherapeutics Anticuerpo humanizado anti-pd-1 humana
WO2020165374A1 (en) 2019-02-14 2020-08-20 Ose Immunotherapeutics Bifunctional molecule comprising il-15ra
TW202202521A (zh) * 2020-03-23 2022-01-16 美商必治妥美雅史谷比公司 用於治療癌症之抗ccr8抗體
CN121270708B (zh) * 2025-12-08 2026-03-17 宁波大学附属第一医院 一种纳米抗体及其在制备cd176阳性肿瘤癌症治疗或诊断药物中的应用
CN121270707B (zh) * 2025-12-08 2026-03-17 宁波大学附属第一医院 一种特异性结合cd176蛋白的纳米抗体及其应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050260680A1 (en) * 2004-04-16 2005-11-24 Vanderbilt University Methods of diagnosing and treating autoimmune diseases
US7374755B2 (en) * 2004-07-26 2008-05-20 The Research Foundation Of State University Of New York Therapeutic use of anti-TF-Antigen antibody
GB0510790D0 (en) * 2005-05-26 2005-06-29 Syngenta Crop Protection Ag Anti-CD16 binding molecules
WO2007109747A2 (en) 2006-03-21 2007-09-27 Wyeth Methods and compositions for antagonism of rage
EP2161031A1 (en) * 2008-09-05 2010-03-10 SuppreMol GmbH Fc gamma receptor for the treatment of B cell mediated multiple sclerosis
AU2010306119A1 (en) * 2009-10-16 2012-05-03 Centre National De La Recherche Scientifique (Cnrs) Monoclonal antibodies to progastrin and their uses
EP2347769A1 (en) * 2010-01-20 2011-07-27 Glycotope GmbH Cancer stem cell markers and uses thereof
EP2407487A1 (en) * 2010-07-14 2012-01-18 F-Star Biotechnologische Forschungs - und Entwicklungsges. M.B.H. Multispecific modular antibody
AU2012245116A1 (en) 2011-04-20 2013-11-07 Genmab A/S Bispecific antibodies against HER2 and CD3
BR112014013081A2 (pt) * 2011-11-30 2020-10-20 Chugai Seiyaku Kabushiki Kaisha veículo contendo fármaco em célula para formação de um complexo imune
CN102796144A (zh) * 2012-08-22 2012-11-28 山东大学 Tf抗原及其类似物、和其化学酶法合成方法及其应用
US10023651B2 (en) * 2014-04-18 2018-07-17 The Research Foundation For The State University Of New York Humanized anti-TF-antigen antibodies

Also Published As

Publication number Publication date
CA2943681A1 (en) 2015-10-22
RU2699717C2 (ru) 2019-09-09
US11130821B2 (en) 2021-09-28
BR112016024214B8 (pt) 2023-12-26
JP2017518260A (ja) 2017-07-06
WO2015161311A2 (en) 2015-10-22
BR112016024214A2 (pt) 2018-01-23
BR112016024214B1 (pt) 2023-11-14
RU2016143552A3 (enExample) 2018-11-14
AU2015247358A1 (en) 2016-11-10
AU2015247358B2 (en) 2020-02-27
MX378944B (es) 2025-03-10
CN106488774A (zh) 2017-03-08
EP3797793A1 (en) 2021-03-31
CN106488774B (zh) 2019-11-01
MX2016013686A (es) 2017-03-31
RU2016143552A (ru) 2018-05-21
EP3131581A2 (en) 2017-02-22
MX2021000439A (es) 2021-03-25
JP6740135B2 (ja) 2020-08-12
EP3131581B1 (en) 2020-09-23
KR20170010356A (ko) 2017-01-31
US20180258182A1 (en) 2018-09-13
EP3131581A4 (en) 2018-02-21
WO2015161311A3 (en) 2015-12-10
KR102413809B1 (ko) 2022-06-28

Similar Documents

Publication Publication Date Title
ES2843546T3 (es) Anticuerpos humanizados anti-antígeno-TF
JP2022137018A (ja) 特異的結合タンパク質およびこれらの使用
US9409994B2 (en) High-affinity monoclonal antibodies to glypican-3 and use thereof
US11427648B2 (en) Anti-CD146 antibodies and uses thereof
ES2527521T3 (es) Anticuerpos antihumanos frente a Dlk-1 que tienen actividad antitumoral
JP7353187B2 (ja) 抗ｌ１－ｃａｍ抗体およびその使用
AU2018220085B2 (en) Humanized monoclonal antibodies and methods of use for the diagnosis and treatment of colon and pancreas cancer
CN114401744A (zh) 用于治疗癌症的抗cd33抗体
US10023651B2 (en) Humanized anti-TF-antigen antibodies
CA2943681C (en) Humanized anti-tf-antigen antibodies
KR101380057B1 (ko) 췌장암의 진단제 및 치료제
HK40042631A (en) Humanized anti-tf-antigen antibodies
JP2020524527A (ja) ヒト腫瘍幹細胞をターゲティングするモノクローナル抗体及びその使用
ES3057459T3 (en) Transthyretin antibodies and uses thereof
HK1233512B (en) Humanized anti-tf-antigen antibodies
JP2017024991A (ja) 抗カドヘリン１７抗体及び胃がん体外イメージング剤
JP2010280568A (ja) 肺癌、前立腺癌、乳癌、卵巣癌、及びメラノーマの診断薬および治療剤
JP2011001267A (ja) 大腸癌治療薬